Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7022782 | 0.89 | TACR1 (0.38) | TACR1SLC6A2CHRNA7SLC6A4 | |
| SCHEMBL7022942 | 0.89 | TACR1 (0.48) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7028814 | 0.88 | TACR1 (0.47) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7031582 | 0.87 | TACR1 (0.48) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7031399 | 0.87 | TACR1 (0.44) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7031400 | 0.87 | TACR1 (0.44) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7019767 | 0.85 | TACR1 (0.50) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7019769 | 0.85 | TACR1 (0.50) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7031573 | 0.85 | TACR1 (0.53) | TACR1SLC6A2SLC6A3ADRA1AHTR2B | |
| SCHEMBL7031575 | 0.85 | TACR1 (0.53) | TACR1SLC6A2SLC6A3ADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | claimed |
| EP-0734381-B1 | MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-07-05 | — | — | EP | claimed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | claimed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | claimed |
| US-6638930-B2 | Antiinflammatory agents, analgesics, antiasthmatics, antiemitics and calcium channel blockers for angina, hypertension or ischemia | MERCK & CO. INC. | 2003-10-28 | — | — | US | disclosed |
| EP-0748320-B1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | disclosed |
| US-6235735-B1 | AFTERTREATMENT OF RADIATION THERAPY | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0734381-B1 | MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5922706-A | TREATING INFLAMMATORY DISEASES, PAIN OR MIGRAINE, ASTHMA AND EMESIS, AND CALCIUM CHANNEL BLOCKERS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS SUCH AS ANGINA, HYPERTENSION OR ISCHEMIA | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5691336-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; THERAPY OF ASTHMA, EMESIS | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5637699-A | CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENT | MERCK & CO., INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0734381-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | TRPM7, TRPM2, TRPM5 | TACR1 23/4885SLC6A2 1902/4885SLC6A3 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.